Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Geron Corporation Trends and Insights

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing operational costs is crucial. This chart highlights the Selling, General, and Administrative (SG&A) expenses of Sarepta Therapeutics, Inc. and Geron Corporation from 2014 to 2023. Over this period, Sarepta's SG&A expenses surged by nearly 900%, reflecting its aggressive growth strategy and expansion efforts. In contrast, Geron Corporation's expenses increased by approximately 310%, indicating a more conservative approach.

Key Insights

Sarepta's expenses peaked in 2023, reaching nearly 482 million, a testament to its rapid scaling and investment in infrastructure. Meanwhile, Geron's expenses, though significantly lower, showed a steady rise, culminating in 69 million in 2023. This divergence in financial strategy underscores the different paths these companies have taken in the biotech landscape. Understanding these trends offers valuable insights into their operational priorities and market positioning.